Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Ishy PL, Fagerlund B, Broberg BV, et al
The present review ultimately weighs early concerns against increasingly consistent evidence that GLP-1 RA use does not raise overall cancer risk, clarifies that breast cancer risk appears neutral, and further highlights key mechanisms, such as the reduction of hyperinsulinemia and immune-microenvironment modulation, through which these drugs may improve rather than exacerbate malignancy outcomes
(a) Epitope tags may have diverse, deleterious structural and functional effects on target proteins
This representation of RAND intellectual property is provided for noncommercial use only
US$ 22.98
US$ 23.94
US$ 27.38
US$ 29.68
